Workflow
BesTrade DeAI Agent
icon
Search documents
AIxC Appoints Andrew Grossman As Head of Legal Where He Will Direct the Company's Legal, Compliance, and Governance Strategy
Prnewswire· 2025-12-17 06:01
Core Insights - AIxCrypto Inc. has appointed Andrew Grossman as Head of Legal to oversee legal, compliance, and governance functions, focusing on SEC disclosures and strategic agreements [1][2][3] - The company recently rebranded from Qualigen Therapeutics, Inc. to AIxCrypto Holdings, Inc., aiming to integrate AI and blockchain technologies while bridging Web2 and Web3 [4][5] Company Strategy - AIxCrypto is positioned at the intersection of Web3 and AI, with a commitment to responsible innovation and sustainable commercial value [3] - The company aims to create a leading ecosystem that connects AI, crypto, and blockchain technologies, establishing itself as a gateway to the emerging AI Web3 landscape [4][5] Leadership and Compliance - Andrew Grossman brings extensive experience in securities regulation and corporate governance, which will enhance AIxCrypto's compliance framework [2][3] - His leadership is expected to strengthen the company's compliance capabilities and support long-term regulatory alignment, particularly in collaboration with Faraday Future Intelligent Electric, Inc. [3]
YT Jia, Chief Advisor to AIxC Shares Weekly AIxC Investor Update: AIxC Appointed Andrew Grossman as Head of Legal Where he will Take Full Responsibility for the Company's Legal, Compliance, and Governance Framework
Prnewswire· 2025-12-15 04:44
Core Insights - AIxCrypto Inc. has transitioned to a dual public company structure and will provide weekly updates on its dual flywheel businesses [1][2] - The company has appointed Andrew Grossman as Head of Legal, who will oversee legal, compliance, and governance frameworks [3][4] - AIxCrypto has rebranded from Qualigen to focus on integrating AI and blockchain technologies, aiming to create a leading ecosystem that bridges Web2 and Web3 [5] Company Developments - The appointment of Andrew Grossman is expected to enhance AIxCrypto's compliance capabilities, particularly in areas such as SEC disclosures and digital asset regulation [3][4] - AIxCrypto's strategy includes leveraging compliance foundations established at Faraday Future to ensure long-term regulatory alignment [4] - The company aims to become the primary gateway to the AI Web3 world, focusing on products like the BesTrade DeAI Agent and other ecosystem offerings [5] Business Strategy - AIxCrypto is committed to building a world-leading ecosystem that integrates AI and blockchain technologies [5] - The company emphasizes the importance of compliance and governance in its operations to maximize long-term commercial value [3][4] - The dual flywheel business model is designed to drive growth across multiple sectors, including AI and cryptocurrency [1][2]
贾跃亭和FF投资的美股上市公司QLGN将11月12日股东大会后更名为 AIxCrypto
Sou Hu Cai Jing· 2025-10-28 14:05
Core Insights - Faraday Future Intelligent Electric Inc. has made a strategic investment in Qualigen Therapeutics Inc., which will be renamed AIxCrypto after the shareholder meeting on November 12, 2025 [1][2] - The investment amounts to over $41 million, with Faraday Future contributing approximately $30 million for a 55% stake, while founder Jia Yueting invests $4 million for a 7% stake [2] - AIxCrypto plans to launch new Web3 and cryptocurrency initiatives, including the public testing of BesTrade DeAI Agent and the release of the EAI RWA Utility token white paper by the end of November [2][3] Investment Details - Faraday Future's investment is led by Jia Yueting and includes participation from Binance Labs, Sequoia Capital, IDG, and Circle [1] - After the investment, Faraday Future and Jia Yueting will collectively hold about 62% of Qualigen Therapeutics [2] Business Strategy - AIxCrypto aims to achieve three key milestones by the end of 2025: 1. Expand the asset management scale of C10 Treasury to $50 million, enhancing its role as a core reserve asset in the Web3 ecosystem [2] 2. Accelerate the global growth of BesTrade DeAI Agent, establishing it as a top AI trading platform [3] 3. Launch a Crypto ecosystem token on leading exchanges, creating a sustainable on-chain value growth system [3]
贾跃亭和FF投资控股上市公司QLGN,11月股东大会后更名AIxCrypto
Sou Hu Cai Jing· 2025-10-28 14:05
Core Insights - Qualigen Therapeutics Inc. (QLGN) will rebrand to AIxCrypto after its shareholder meeting on November 12, 2025, and has set three core objectives for 2025 [1][2] Group 1: Business Strategy - QLGN has initiated a new Web3 and cryptocurrency business plan, with the public beta of BesTrade DeAI Agent set to launch at the end of November [1][2] - The first milestone aims to expand the C10 Treasury's asset management scale to $50 million, enhancing its role as a core reserve asset in the Web3 ecosystem [1] - As of October 17, 2023, QLGN's C10 Treasury has completed a $12 million allocation in cryptocurrency assets [1] Group 2: Product Development - The second milestone focuses on accelerating the global growth of BesTrade DeAI Agent, which is designed to optimize trading paths and returns, establishing itself as a leading AI trading platform [2] - The third milestone involves launching the Crypto ecosystem Token on leading exchanges, which will consist of C10 stablecoin and EAI+Crypto products, aiming to create a sustainable on-chain value growth system [2] Group 3: Investment Details - Faraday Future Intelligent Electric Inc. (FFAI), led by founder Jia Yueting, has made a strategic investment in QLGN, with the total investment expected to exceed $41 million, subject to shareholder approval [3] - FFAI invested approximately $30 million for about 55% ownership in QLGN, while Jia Yueting personally invested around $4 million for about 7% ownership [3] - Post-investment, FFAI and Jia Yueting will collectively hold approximately 62% of QLGN, with FFAI gaining significant board representation [3]
Qualigen Therapeutics to Rebrand as AIxCrypto After Stockholder Meeting on November 12, with Three Core Goals for 2025
Globenewswire· 2025-10-28 03:57
Core Viewpoint - Qualigen Therapeutics Inc. will rebrand as AIxCrypto following its stockholder meeting on November 12, 2025, and is launching new initiatives in the Web3 and crypto asset sectors [1] Group 1: Rebranding and New Initiatives - The company will officially change its name to AIxCrypto and introduce its new business initiatives in the crypto space [1] - AIxCrypto plans to launch the public beta of its BesTrade DeAI Agent by the end of November 2025 and release its EAI RWA Utility Token Whitepaper [2] Group 2: Strategic Goals - AIxCrypto aims to expand the C10 Treasury to $50 million in assets under management (AUM), having completed $12 million in crypto asset allocations as of October 17, 2025 [2] - The company intends to accelerate global growth of the BesTrade DeAI Agent, which will serve as a Meta Exchange optimizing transaction pathways and returns [3] - AIxCrypto plans to launch crypto ecosystem tokens on leading exchanges, supported by a potential C10 stablecoin and EAI + Crypto RWA dual-bridge products [4] Group 3: Company Background - Qualigen Therapeutics, Inc. is a biotechnology company based in Carlsbad, California, focusing on innovative oncology and immunology therapies while expanding into crypto asset and Web3 strategies [5]
Faraday Future Announced a Total Strategic Investment of $41 million in Qualigen Therapeutics, Inc. (NASDAQ: QLGN) During its Annual 919 Event, for its Crypto Business Focusing on Three Growth Engines
Globenewswire· 2025-09-22 00:00
Core Viewpoint - Faraday Future Intelligent Electric Inc. is strategically investing approximately $30 million in Qualigen Therapeutics, Inc. to initiate a crypto and web3-related business, aiming to enhance its dual-flywheel and dual-bridge eco strategy to maximize shareholder value [1][2][8] Investment Details - The total investment in Qualigen Therapeutics will be around $41 million, with Faraday Future contributing about $30 million for approximately 55% of QLGN's common stock on a pro forma basis [2][3] - YT Jia, Founder & Global Co-CEO, will invest $4 million and receive about 7% of QLGN's common stock, with a two-year lockup on his shares [3][4] Management and Governance - Faraday Future plans to assign management teams to oversee relevant business activities, with YT Jia serving as chief advisor to QLGN and Jerry Wang expected to be appointed as Co-CEO [4] - Following the investment, Faraday Future will have the right to nominate two of five directors on QLGN's board, which could increase to four of seven if stockholder approval is obtained [4] Rebranding and Product Focus - Qualigen Therapeutics is expected to rebrand as CXC10, focusing on three growth engines in the crypto ecosystem, including the C10 Treasury, BesTrade DeAI Agent, and ecosystem tokens [5][6][7] - The C10 Treasury has shown an unrealized gain of around 7%, outperforming the C10 index, with a 20% actively managed allocation yielding positive results [9] Product Innovations - The FX Super One MPV was showcased at the annual 919 event, featuring an ultra-wide dual-screen panoramic display and advanced EAI OS for enhanced user interaction [10][12][13] - The EAI Space in the FX Super One is designed to provide a personalized and immersive experience, integrating hardware, software, and applications for seamless user engagement [15][16][17] Future Outlook - Faraday Future aims to bridge Web2 and Web3, as well as AI and crypto, positioning itself as a leading U.S. public company in the evolving digital landscape [6][9]